BeOne cashes in its Imdelltra royalty
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
The first clinical-stage dual-payload conjugate
Chengdu Kanghong's KH815 enters human testing this month.
ASH 2024 movers – moments of reckoning for menin and BTK
Menin, BTK and a Car-T skirmish featured over the ASH weekend.
ASH 2024 – Arcellx is happy to share in Car-T
Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.
ASH 2024 preview – Arcellx disappoints
An ASH abstract reveals no delayed neurotoxicity, but three deaths, with anito-cel.
